Finance

Italy set to speed through $2.3 billion Novo Nordisk investment

Published by Global Banking & Finance Review

Posted on July 7, 2025

2 min read

· Last updated: January 23, 2026

Add as preferred source on Google
Italy set to speed through $2.3 billion Novo Nordisk investment
Global Banking & Finance Awards 2026 — Call for Entries

ROME (Reuters) -Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its promised 2 billion-euro ($2.34 billion) investment in a

Italy Appoints Commissioner to Accelerate $2.3 Billion Novo Nordisk Investment

ROME (Reuters) -Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its promised 2 billion-euro ($2.34 billion) investment in a factory south of Rome.

As part of Novo Holdings' takeover of pharmaceutical company Catalent last year, Novo Nordisk acquired a site in Italy along with two others, one in Belgium and one in the United States.

Francesco Rocca, president of the Lazio region that includes Rome and is where the Anagni factory is based, was made special commissioner for the site, a role that gives him powers to speed up projects related to the facility, including upgrades.

The factory will produce weight loss and diabetes drugs, the region said in a statement, adding that Rocca's appointment "aims to ensure administrative speed and institutional coordination, essential elements for a project of this magnitude".

Speaking at a news conference, Rocca said production is scheduled to start in late 2026 or early 2027 and the factory upgrade should be fully completed in 2029.

Novo Nordisk in an emailed statement declined to provide details on what would be manufactured at the site, but welcomed the Italian government's support.

Italy's government approved Novo's plans to upgrade capacity at the Anagni site in March, saying the company had pledged to invest more than 2 billion euros in 2025-2029 and hire around 800 people, boosting the total workforce to 1,500. 

The government declared the plans to be of "pre-eminent strategic interest", a status granted to large foreign investment projects that allows the fast-tracking of approval procedures.  

The Lazio region said on Monday it had approved upgrades for road links to the factory worth more than 2.9 million euros.

($1 = 0.8530 euros)

(Reporting by Alvise Armellini, additional reporting by Louise Rasmussen in Copenhagen; editing by Barbara Lewis)

Key Takeaways

  • Italy appoints a commissioner to expedite Novo Nordisk's investment.
  • Novo Nordisk plans a $2.3 billion upgrade at the Anagni site.
  • The factory will produce weight loss and diabetes drugs.
  • Production is set to begin in late 2026 or early 2027.
  • The project will create approximately 800 new jobs.

Frequently Asked Questions

What is the amount of Novo Nordisk's investment in Italy?
Novo Nordisk is set to deliver a promised investment of 2 billion euros, which is approximately $2.34 billion.
Who was appointed as the special commissioner for the Novo Nordisk project?
Francesco Rocca, the president of the Lazio region, was appointed as the special commissioner to oversee the project.
When is production expected to start at the Anagni factory?
Production at the Anagni factory is scheduled to start in late 2026 or early 2027.
What is the strategic significance of Novo Nordisk's plans in Italy?
The Italian government declared Novo's plans to upgrade the Anagni site as of 'pre-eminent strategic interest', allowing for fast-tracked approval procedures.
How many jobs is Novo Nordisk expected to create in Italy?
Novo Nordisk has pledged to hire around 800 people as part of its investment in Italy.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category